The National Institutes of Health has selected three new proof-of-concept hubs to help speed the translation of basic biomedical discoveries into commercial products, such as new drugs, devices, and diagnostics, to improve patient care and enhance health. The hubs are part of the NIH-supported Research Evaluation and Commercialization Hubs (REACH) program and will be funded at $9 million over three years.
REACH is based on an initiative created by the NIH’s National Heart, Lung, and Blood Institute (NHLBI) called the NIH Centers for Accelerated Innovations (NCAI). These centers are a unique public-private partnership whose objective is to change how to identify and develop innovations with scientific and commercial potential. The effort utilizes industry-style project management to arrive at technologies that are poised to launch. With the addition of the REACH, NIH has created a nationwide network of six centers and hubs to develop best practices in translating academic innovations into products to improve health.
The hubs will foster the development of therapeutics, preventatives, diagnostics, devices, and tools that address diseases within the NIH’s mission in a manner consistent with business case development. Each hub will provide funding for feasibility studies and coordinated access to expertise in areas required for early stage technology development, including scientific, regulatory, reimbursement, business, legal, and project management. In addition, the hubs will provide skills development and hands-on experience in entrepreneurism.
“NIH is committed to ensuring that the American people benefit from the many promising discoveries supported by taxpayers,” said Dr. Kurt Marek, program director for REACH and the deputy director of the Office of Translational Alliances and Coordination, NHLBI. “The REACH program will accelerate the translation of those discoveries into new drugs, devices, and diagnostics to help patients and improve public health.”
The REACH program will take advantage of the NCAI’s established infrastructure and relationships, including partnerships with the U.S. Food and Drug Administration, the United States Patent Office, and the Centers for Medicare & Medicaid Services. The REACHs and NCAIs will work collaboratively, share resources when appropriate, and develop best practices that will be made available to the public. To enhance the scope and impact of the NIH investment, each REACH has secured non-federal funding equal to or greater than the NIH award and developed partnerships with other regional public and private organizations.
REACH is a trans-NIH program and will be overseen by a committee with representatives from across the agency. NHLBI will manage the effort due to the institute’s experience with NCAI and to ensure collaboration between the programs.
“We are happy to lead the management of the REACH program in concert with our NIH and federal partners,” said Dr. Jodi Black, deputy director, Division of Extramural Research Activities, NHLBI. “In just 18 months, the NCAIs have already learned many lessons about how best to perform proof-of-concept work and we are excited to scale this model to the three new REACH locations.”
The new REACH awardees are:
The Long Island Bioscience Hub: Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, New York
The University of Louisville, Kentucky
The University of Minnesota, Minneapolis
The existing NCAI awardees are:
- Boston Biomedical Innovation Center: Brigham and Women’s Hospital, Boston Children’s Hospital, Massachusetts General Hospital, and President and Fellows of Harvard College
- Cleveland Clinic Innovation Accelerator: The Cleveland Clinic Lerner College of Medicine; Case Western Reserve University, Cleveland; Cincinnati Children’s Hospital; The Ohio State University, Columbus; and University of Cincinnati
- University of California BRAID Center for Accelerated Innovation: University of California, Los Angeles; University of California, Davis; University of California, Irvine; University of California, San Diego; and University of California, San Francisco
For more information, please contact the NIH Office of Extramural Research’s Division of Communications at 301-435-4642.